Loading
A phase 1/2 trial of AVZO-021 and Fulvestrant in advanced solid tumours, run by Avenzo Therapeutics, Inc., now recruiting.
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06998407 by Avenzo Therapeutics, Inc., with 380 participants planned, started 2025-08-20 and due to reach its primary completion in 2028-08. Interventions recorded: AVZO-021, Fulvestrant, Letrozole and AVZO-023.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Avenzo Therapeutics and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/